{"name":"Neos Therapeutics, Inc","slug":"neos-therapeutics-inc","ticker":"","exchange":"","domain":"","description":"","hq":"","founded":0,"employees":"","ceo":"","sector":"","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[{"name":"Neuroscience","slug":"neuroscience","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"oncology","drugs":[{"name":"NT0102","genericName":"NT0102","slug":"nt0102","indication":"Attention-deficit/hyperactivity disorder (ADHD) in children and adolescents","status":"phase_3"}]}],"pipeline":[{"name":"NT0102","genericName":"NT0102","slug":"nt0102","phase":"phase_3","mechanism":"NT0102 is a prodrug formulation of methylphenidate designed to provide extended-release delivery with reduced abuse potential.","indications":["Attention-deficit/hyperactivity disorder (ADHD) in children and adolescents"],"catalyst":""}],"recentEvents":[],"realNews":[{"url":"https://news.google.com/rss/articles/CBMiyAFBVV95cUxPRTh1YUJoOHdkVlR2czVJREZCb19BeGdPQ2VicnBiWE80ajE3TXQ3eGZaZS1RRGVmekx6THcxTmRuLS1pYWd4czloZVJRbkU3dXVydVZyWDZ3c2ZqX05yWlY4U0g1ZTVtVm8tQXdhSXcxUjBhRWF4dWozemQwRldOZ0puMkN0VmJfcUZ1YWZ6QmxweVM3RU5kaUpSckEyZnBrMndjWldFT3VOQnlGSVFxUGlpRzVaNjN5dk1qWDZqcUMtcGNBNXZvVA?oc=5","date":"2026-04-03","type":"pipeline","source":"Stock Titan","summary":"Executive pay and board elections at Harmony Biosciences (HRMY) 2026 virtual meeting - Stock Titan","headline":"Executive pay and board elections at Harmony Biosciences (HRMY) 2026 virtual meeting","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiWEFVX3lxTE9BN2ROZFZXbU8yYmpwcVdxYnMyY1NocG9NSGRhd2N5T1ZPcHpKS1Z2ckVSY3ZoZXAzbE5PQ0FQLWlpWEV6SmhsX2xFNzUzcE9aeE5paUtla2M?oc=5","date":"2026-03-09","type":"pipeline","source":"TradingView","summary":"HELP Stock Price and Chart — NEO:HELP - TradingView","headline":"HELP Stock Price and Chart — NEO:HELP","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMigAFBVV95cUxNa2pCT3d4OV95NmJPX3MtWDgwUjdudWVqbkJ6cXdiNDRXaTFpcTVQX0wwX2xUZ2hIekg0SC0tenFCc1QxYXlqZzR4eUZ6RnRVcFZZZWNMR1VIbzQzMlBfYUVuQm5WZzJBN1l5ak8zRVByNGZ3RjM5cVhsNnk1d0xWUQ?oc=5","date":"2025-08-28","type":"pipeline","source":"NEOtrans","summary":"Abeona Therapeutics to expand in Midtown - NEOtrans","headline":"Abeona Therapeutics to expand in Midtown","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi2AFBVV95cUxQNkMtSEV3WHdXemdyX3V3YnVRZEtOQzZPdzJRc0lMQXJYaWs4N0NmVVpMcmotclJfY0lBSEZBdDkwd3lYblRjdGtxeVZra2dtWXVoZlI2V3pnUkNaOTczcDhaWVJ6RWFKS2t2azhReUVRR05ISkdMMzBIWWNmb0JmNW1ta09SODFibmw5MDRoYlBfcXdmWWlOa2lmaUxUTTI1LXV5YXRtYUMxWjlhWTVPc1VGSVJ4QnZuZlU3cHpaN3N3OEtTaE5GUDR2U0dPUDdUc29ZQlV3V20?oc=5","date":"2025-03-31","type":"pipeline","source":"businesswire.com","summary":"USAntibiotics Names Mark Tengler Senior Vice President of Manufacturing Technologies - businesswire.com","headline":"USAntibiotics Names Mark Tengler Senior Vice President of Manufacturing Technologies","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMihwFBVV95cUxPaFJ2UmpXT0NPWEI2VEJPZU9ZS1ZCTVpET3JjWXhHS3lqNWRBV1FOckdPamhVNV9Da3B2dUtLTmE3c1VFV1ozMEY3VjhNSVBGWFRUcXFoNXZfVHpMSmZ5M2pmZjQweXA2NGZsT1RnRmFwWlhZcGhRX2xZTDFfeDgzV293bkE0NUU?oc=5","date":"2025-02-13","type":"pipeline","source":"Market.us","summary":"Attention Deficit Hyperactivity Disorder Market Size | CAGR of 7.6% - Market.us","headline":"Attention Deficit Hyperactivity Disorder Market Size | CAGR of 7.6%","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi5AFBVV95cUxQSVZuTVE5dFAxT0U4SzFaWXBoNklFWmhoSUl5NllLaHZIdzFMdHk4UGEyejBWT0dPdEtaRVl4QmdBbGxESUo1Yjk0c29uclZTaWpCajNiY09MdFlLSUV4UVFwTDJkVUpPTEhHbHFOa0xnNnRLcXRCQWFPTWljTTdiZm1pR1N0akpYdXMwa3E1R3M0ZHd0aVJJc0d2ZHYyRlh1WE1WYUw1ODBEWTVpZGpLRmplYWhXa3pkaUhCZkN4czJPb1ZONzk2TkRhQUJoTS1WU1dDNER1aEl1LTJkWFhqRGZadXQ?oc=5","date":"2021-06-22","type":"regulatory","source":"Psychiatrist.com","summary":"Symptomatic and Functional Response and Remission From the Open-Label Treatment-Optimization Phase of a Study With DR/ER-MPH in Children With ADHD - Psychiatrist.com","headline":"Symptomatic and Functional Response and Remission From the Open-Label Treatment-Optimization Phase of a Study With DR/ER","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi3AFBVV95cUxQVk93SEVjaXpUMFdSMWZCamxHTnc2eTMtSW0zanQxTzFNZTZtSVZRSDh1clNEY1lfRS05c0loSXZodkl6WUJLcUNHYmV4dFVOaFpYOHZXOFBPZnFfSzFfUEpyOGNhbmRRQi13LWFIdy15MTB5WDdtOVFSUjdHc2RBVXRjd0hBQ1dvVE1NV0JSSmVOS0VDc1FtYVh0WXZxQ193aVJrOVZGQ2lxaWstVWtwckZ6UW9HdVJLVWxBc3dLSEtpR0Y2Ynh3aGEzM3RNNm8wMlo2YWt1ckhoaExy?oc=5","date":"2021-03-22","type":"deal","source":"ACCESS Newswire","summary":"Aytu BioScience Announces Close of Merger with Neos Therapeutics - ACCESS Newswire","headline":"Aytu BioScience Announces Close of Merger with Neos Therapeutics","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiowFBVV95cUxOd0J0Y3BnM0Z3NlgxTnYzV2tPY2NLb09Wc0lqYUpDT1hNd3NLZHY5anl3Wno4QmI2Ukdnc2J5SWN4MmJ4bjdRSGFHRWxIVVh6REcyUmZTM3NtQmpFN1VWYmhkOHlIREdzWTJvb25vSnZ4WE5yel9RUU1WeDdIc1oyY2pTTEJtQjdOM2Yxcm5lZGtwdkdBY3k1NmhLay05bzRhd1Jr0gGoAUFVX3lxTE1PTE5GRDVnb21RWkphVEVHZ1ZnM2tuOGppZjM5dWUzTGNyYm9CWXBKUFBVV0lLMDl4ZFFDdDBzQkpSYThnUGJDTC1lbko1bzdiQkpEUGZDS0s5MDlwbFNmQng3N1lIZUVoVU00ZzZ3S1FZLXUtREdzTm1TSk9WQ1ozWkVCdnpxN0xrNnMzYmxtN1EtdlRwRGVkbGtPOVhKUU5QVFRPQzdFeA?oc=5","date":"2020-01-03","type":"pipeline","source":"CBS News","summary":"Big Pharma companies raised prices on more than 400 drugs to start 2020 - CBS News","headline":"Big Pharma companies raised prices on more than 400 drugs to start 2020","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiogFBVV95cUxNdXdOSmpyTkp1SjllWExPcEcxOC1YSl95ZTE1WEMyb0dGdXpZd2NONE5SRnd2eUxTUzE3LW5TYXdTWE1aWE4zckNKemFHalU1V29iaDY5RnlBSHd1WkFsZ3hFQll5MVNTUFZJV016dTZRLXdqa1BuODdOX21ZQkQyWTc2a296MkVudzlORmRLd1dMd0dkb3NYanY3N0pJcndqRGc?oc=5","date":"2019-02-05","type":"pipeline","source":"Dallas Innovates","summary":"DI People: Neiman Marcus, Pier 1, Crayon, Neos Therapeutics Make Exec Moves - Dallas Innovates","headline":"DI People: Neiman Marcus, Pier 1, Crayon, Neos Therapeutics Make Exec Moves","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiuAFBVV95cUxPdjdLYTBodHVqcDhhMk1mZllMZVkyMkZnbjMwVkhpdGc3OTJWNjVLM3FjWHFfUDVQRl8yT0ZtWDl3NFJaYjl2OVFLOXljYlRlaGtDdkV0bGRJRUQtcmZkOGdFNm9RRXdJRkNKMHVSNkttNGVxQVU1VGM2MkhrY3lETjRMYzlrNUVJdVJVS0c3eW5mLXZSLXpfWVNoOUxYYmlPSEt5dmE2NmhPWWhxWE9DSldtWUh6dThs?oc=5","date":"2018-10-29","type":"deal","source":"BioSpace","summary":"Neos Therapeutics Licenses Pipeline Candidate for Treatment of Sialorrhea (Excessive Drooling) - BioSpace","headline":"Neos Therapeutics Licenses Pipeline Candidate for Treatment of Sialorrhea (Excessive Drooling)","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiVkFVX3lxTE5NVE9TdzZiN2JEclJvV3djYjZJNUlaalA3SWJlN19DRjFTb0tGbE55NDNYNmRzY19nSVRwOVByc19fSUdJdW1GQ1Y4dk02eHZ2bjRpNk9R?oc=5","date":"2017-09-19","type":"regulatory","source":"Medscape","summary":"FDA Clears Liquid Extended-Release Amphetamine for ADHD - Medscape","headline":"FDA Clears Liquid Extended-Release Amphetamine for ADHD","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMipAFBVV95cUxOLXdRWEp3RzN3ZTlfOV9VYXZnSnR6MmQ4SVBoc3Jpc0dRczZPdFYydGhrX21HM1pHaEsxZnBWdGtQamR0YV9aZ1JrVEh1M1NjSFFUQ3V5cG9EVXVCWE1mUU1FQ2pLYS1sQjl3emRwNkFERzl0TllBU1U4RkY3dVNlVXBXMW5FZENLNTcweTQtc0htNE4xMFVSSnpOTGh5TjFyMEc5Sw?oc=5","date":"2016-08-02","type":"pipeline","source":"Hamilton College","summary":"Paul Edick ’77 Joins Sucampo Pharmaceuticals, Inc. Board of Directors - Hamilton College","headline":"Paul Edick ’77 Joins Sucampo Pharmaceuticals, Inc. Board of Directors","sentiment":"neutral"}],"patents":[],"drugCount":1,"phaseCounts":{"phase_3":1},"enrichmentLevel":0,"visitCount":2,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}